 |
|
|
| 1682 |
|
The first bone transplantation is recorded. |
|
| 1870 |
|
The first completely documented human tissue
grafting is performed in by a Swiss surgeon, Dr. Jacques Reverdin. |
|
| 1905 |
|
Dr. Edward Zirm performs the first corneal transplant. |
|
| 1908 |
|
Dr. Reverdin performs the first skin allograft. |
|
|
|
Dr. Eric Lexer performs the first successful
cadaver knee joint transplant. |
|
| 1911-1912 |
|
The French surgeon, Alexis Carrel, develops methods
of joining blood vessels utilizing cadaveric vessels that made the
transplantation of organs feasible. |
|
| 1937 |
|
March 15th: Bernard Fantus, director of therapeutics at the Cook County Hospital in Chicago, established the first hospital-based blood bank in the United States. |
|
| 1949 |
|
The US Navy Tissue Bank is established. |
|
| 1955 |
|
The initial fresh heart valve allograft is placed
into the descending aorta. |
|
| |
|
The first frozen venous allograft is utilized for femoral artery
bypass. |
|
| 1962 |
|
The first fresh heart valve is implanted into
the cardiac position. |
|
| 1971 |
|
The first frozen heart valve is used as an allograft. |
|
|
|
Cryopreserved human skin allograft is introduced. |
|
| 1974 |
|
Cryopreserved venous allograft is first used. |
|
| 1976 |
|
The American Association of Tissue
Banks (AATB) is founded to facilitate the provision of transplantable tissue and
cells of uniform quality in quantities sufficient to meet national
needs. |
|
| 1984 |
|
National Transplant Act (NOTA)
(Public Law 98.507) establishes the National
Task Force on Organ Transplantation. This Act makes legal, a centralized
waiting list for organ recipients and outlaws the purchase or sale
of organs. |
|
| December 1993 |
|
Food and Drug Administration (FDA) publishes
interim final rule requiring the screening and testing of tissue donors
for certain transmissible diseases such as HIV and hepatitis, as well
as the screening of donors for behavioral risk factors. |
|
| February 1997 |
|
FDA proposes a new, comprehensive approach to
the regulation of human cellular and tissue-based products. Regulations
will focus on three general areas: |
|
| |
|
(1) Preventing unwitting use of contaminated
tissues with the potential for transmitting infectious diseases such
as AIDS and hepatitis; |
|
| |
|
(2) Preventing improper handling or processing
that might contaminate or damage tissues; |
|
| |
|
(3) Ensuring that clinical safety and effectiveness
is demonstrated. |
|
| July 1997 |
|
FDA issues final rule requiring certain infectious
disease testing, donor screening, and record keeping, helping prevent
the transmission of the human immunodeficiency virus (HIV) and hepatitis
viruses through human tissue used in transplantation |
|
| May 1998 |
|
FDA proposes regulations creating a new, unified
system for registering establishments that manufacture human cellular
and tissue-based products and for listing their products. |
|
| September 1999 |
|
FDA proposes that manufacturers of tissue-based
products screen and test donors for relevant communicable diseases
as safeguards to prevent the transmission of communicable diseases
from infected donors. |
|
| January 2001 |
|
FDA proposes new regulations requiring manufacturers
to follow current good tissue practices, which includes the establishment
of standard operating procedures, quality programs, record keeping
standards, and procedures for tracking tissues from donor to recipient
and from recipient to donor. Also, FDA issues final rule requiring
tissue establishments to register with the agency and list their tissues
and tissue-based products. |
